A Phase 2b, Open-label, Multi-center, Extension Study to Evaluate the Safety and Immunogenicity of a Revaccination Dose of the RSVPreF3 Older Adults (OA) Investigational Vaccine Administered Intramuscularly 18 Months Post-Dose 2 in Adults 60 Years and Older Who Participated in the RSV OA=ADJ-002 Study
Latest Information Update: 14 Sep 2023
Price :
$35 *
At a glance
- Drugs Respiratory syncytial virus vaccine adjuvanted (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms ADJ-002
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 12 Sep 2023 Results assessing tolerability,humoral and CMI response after third dose of selected 120microgm RSVPreF3 OA formulation administered 18 months after the second dose published in the Journal of Infectious Diseases
- 02 Jun 2022 Status changed from active, no longer recruiting to completed.
- 16 Oct 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.